Non-BRCA1/BRCA2 high-risk familial breast cancers are not associated with a high prevalence of BRCAness

被引:1
|
作者
Andersen, Lars v. B. [1 ,2 ]
Larsen, Martin J. [1 ,2 ]
Davies, Helen [3 ,4 ]
Degasperi, Andrea [3 ,4 ]
Nielsen, Henriette Roed [5 ]
Jensen, Louise A. [1 ,2 ]
Kroeldrup, Lone [1 ]
Gerdes, Anne-Marie [6 ]
Laenkholm, Anne-Vibeke [7 ]
Kruse, Torben A. [1 ,2 ]
Nik-Zainal, Serena [3 ,4 ,5 ]
Thomassen, Mads [1 ,2 ]
机构
[1] Odense Univ Hosp, Dept Clin Genet, Odense, Denmark
[2] Univ Southern Denmark, Clin Genome Ctr, Dept Clin Res, Odense, Denmark
[3] Univ Cambridge, Early Canc Inst, Hutchison Res Ctr, Cambridge Biomed Campus, Cambridge CB2 0XZ, England
[4] Addenbrookes Hosp, Addenbrookes Treatment Ctr Lv 6, Acad Lab Med Genet, Cambridge CB2 0QQ, England
[5] European Sperm Bank, Copenhagen, Denmark
[6] Copenhagen Univ Hosp Rigshospitalet, Dept Clin Genet, Copenhagen, Denmark
[7] Zealand Univ Hosp, Dept Surg Pathol, DK-4000 Roskilde, Denmark
关键词
Breast cancer; Hereditary breast cancer; Non-BRCA1; BRCA2; Whole genome sequencing; Mutational signatures; HRDetect; BRCAness; TUMOR MUTATIONAL BURDEN; BRCA2; MUTATIONS; DEFICIENCY; SIGNATURES; PREDICTOR; LANDSCAPE; GENES; TOOL;
D O I
10.1186/s13058-023-01655-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundFamilial breast cancer is in most cases unexplained due to the lack of identifiable pathogenic variants in the BRCA1 and BRCA2 genes. The somatic mutational landscape and in particular the extent of BRCA-like tumour features (BRCAness) in these familial breast cancers where germline BRCA1 or BRCA2 mutations have not been identified is to a large extent unknown.MethodsWe performed whole-genome sequencing on matched tumour and normal samples from high-risk non-BRCA1/BRCA2 breast cancer families to understand the germline and somatic mutational landscape and mutational signatures. We measured BRCAness using HRDetect. As a comparator, we also analysed samples from BRCA1 and BRCA2 germline mutation carriers.ResultsWe noted for non-BRCA1/BRCA2 tumours, only a small proportion displayed high HRDetect scores and were characterized by concomitant promoter hypermethylation or in one case a RAD51D splice variant previously reported as having unknown significance to potentially explain their BRCAness. Another small proportion showed no features of BRCAness but had mutationally active tumours. The remaining tumours lacked features of BRCAness and were mutationally quiescent.ConclusionsA limited fraction of high-risk familial non-BRCA1/BRCA2 breast cancer patients is expected to benefit from treatment strategies against homologue repair deficient cancer cells.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] A screen for germline mutations in the gene encoding CCCTC-binding factor (CTCF) in familial non-BRCA1/BRCA2 breast cancer
    Zhou, XL
    Werelius, B
    Lindblom, A
    BREAST CANCER RESEARCH, 2004, 6 (03): : R187 - R190
  • [42] Patterns and Prevalence of Germline BRCA1 and BRCA2 Mutations among High-Risk Breast Cancer Patients in Jordan: A Study of 500 Patients
    Abdel-Razeq, Hikmat
    Abujamous, Lama
    Jadaan, Dima
    JOURNAL OF ONCOLOGY, 2020, 2020
  • [43] Heterozygous germline mutation in NBS1 among Non-BRCA1/2 Korean patients with high-risk breast cancer
    Kim, H.
    Cho, D. Y.
    Choi, D. H.
    Park, W.
    Huh, S. J.
    Lee, M. H.
    Ahn, S. H.
    Son, B. H.
    Kim, S. W.
    RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S300 - S300
  • [44] Cancers Associated With BRCA1 and BRCA2 Mutations Other Than Breast and Ovarian
    Mersch, Jacqueline
    Jackson, Michelle A.
    Park, Minjeong
    Nebgen, Denise
    Peterson, Susan K.
    Singletary, Claire
    Arun, Banu K.
    Litton, Jennifer K.
    CANCER, 2015, 121 (02) : 269 - 275
  • [45] Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer
    Tilanus-Linthorst, M. M. A.
    Alves, C.
    Seynaeve, C.
    Menke-Pluymers, M. B. E.
    Eggermont, A. M. M.
    Brekelmans, C. T. M.
    BRITISH JOURNAL OF SURGERY, 2006, 93 (08) : 961 - 968
  • [46] Prevalence of BRCA1 and BRCA2 genes mutations in a sample of families with high risk of breast and ovarian cancer in Brazil
    Esteves, V. F.
    Thuler, L. C. S.
    Amendola, L. L. C.
    Frankel, P. P.
    Vieira, R. J. S.
    Koifman, R. J.
    Koifman, S.
    CANCER RESEARCH, 2009, 69 (02) : 353S - 353S
  • [47] Prevalence of BRCA1 and BRCA2 gene mutations in families with medium and high risk of breast and ovarian cancer in Brazil
    Esteves, V. F.
    Thuler, L. C. S.
    Amendola, L. C.
    Koifman, R. J.
    Koifman, S.
    Frankel, P. P.
    Vieira, R. J. S.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2009, 42 (05) : 453 - 457
  • [48] Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
    Hollestelle, Antoinette
    Pelletier, Cory
    Hooning, Maartje
    Crepin, Ellen
    Schutte, Mieke
    Look, Maxime
    Collee, J. Margriet
    Nieuwlaat, Anja
    Dorssers, Lambert C. J.
    Seynaeve, Caroline
    Aulchenko, Yurii S.
    Martens, John W. M.
    van den Ouweland, Ans M. W.
    Weidhaas, Joanne B.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (01) : 79 - 84
  • [49] Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families:: A relative survival analysis from Finland
    Eerola, H
    Vahteristo, P
    Sarantaus, L
    Kyyrönen, P
    Pyrhönen, S
    Blomqvist, C
    Pukkala, E
    Nevanlinna, H
    Sankila, R
    INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (03) : 368 - 372
  • [50] Childhood cancer in families with and without BRCA1 or BRCA2 mutations ascertained at a high-risk breast cancer clinic
    Brooks, Gabriel A.
    Stopfer, Jill E.
    Erlichman, Julie
    Davidson, Rebecca
    Nathanson, Katherine L.
    Domchek, Susan M.
    CANCER BIOLOGY & THERAPY, 2006, 5 (09) : 1098 - 1102